145 related articles for article (PubMed ID: 33892058)
21. Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy.
Fu T; Yi J; Lv S; Zhang B
J Liposome Res; 2017 Sep; 27(3):228-233. PubMed ID: 27601177
[TBL] [Abstract][Full Text] [Related]
22. Ketoroloac tromethamine loaded nanodispersion incorporated into thermosensitive in situ gel for prolonged ocular delivery.
Morsi N; Ghorab D; Refai H; Teba H
Int J Pharm; 2016 Jun; 506(1-2):57-67. PubMed ID: 27091293
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of topical and systemic itraconazole as a broad-spectrum antifungal agent in mycotic corneal ulcer. A preliminary study.
Kalavathy CM; Thomas PA
Indian J Ophthalmol; 2002 Mar; 50(1):71-2; author reply 72. PubMed ID: 12090098
[No Abstract] [Full Text] [Related]
24. Antifungal efficacy of Itraconazole loaded PLGA-nanoparticles stabilized by vitamin-E TPGS: In vitro and ex vivo studies.
Alhowyan AA; Altamimi MA; Kalam MA; Khan AA; Badran M; Binkhathlan Z; Alkholief M; Alshamsan A
J Microbiol Methods; 2019 Jun; 161():87-95. PubMed ID: 30738109
[TBL] [Abstract][Full Text] [Related]
25. Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension.
Zhang K; Yu H; Luo Q; Yang S; Lin X; Zhang Y; Tian B; Tang X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1285-92. PubMed ID: 23562534
[TBL] [Abstract][Full Text] [Related]
26. Medical interventions for fungal keratitis.
Florcruz NV; Peczon I
Cochrane Database Syst Rev; 2008 Jan; (1):CD004241. PubMed ID: 18254043
[TBL] [Abstract][Full Text] [Related]
27. Implementing polymeric pseudorotaxanes for boosting corneal permeability and antiaspergillus activity of tolnaftate: formulation development, statistical optimization, ex vivo permeation and in vivo assessment.
Aziz D; Mohamed S; Tayel S; Makhlouf A
Drug Deliv; 2022 Dec; 29(1):2162-2176. PubMed ID: 35815689
[TBL] [Abstract][Full Text] [Related]
28. Medical interventions for fungal keratitis.
FlorCruz NV; Evans JR
Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD004241. PubMed ID: 25855311
[TBL] [Abstract][Full Text] [Related]
29. Comparison of topical itraconazole 1% with topical natamycin 5% for the treatment of filamentous fungal keratitis.
Kalavathy CM; Parmar P; Kaliamurthy J; Philip VR; Ramalingam MD; Jesudasan CA; Thomas PA
Cornea; 2005 May; 24(4):449-52. PubMed ID: 15829804
[TBL] [Abstract][Full Text] [Related]
30. Comparative studies for ciprofloxacin hydrochloride pre-formed gels and thermally triggered (in situ) gels: in vitro and in vivo appraisal using a bacterial keratitis model in rabbits.
Abdelkader H; Mansour HF
Pharm Dev Technol; 2015 Jun; 20(4):410-6. PubMed ID: 24392945
[TBL] [Abstract][Full Text] [Related]
31. Comparison of thermosensitive in situ gels and drug-resin complex for ocular drug delivery: In vitro drug release and in vivo tissue distribution.
Wei Y; Li C; Zhu Q; Zhang X; Guan J; Mao S
Int J Pharm; 2020 Mar; 578():119184. PubMed ID: 32112932
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo evaluation of cubosomal nanoparticles as an ocular delivery system for fluconazole in treatment of keratomycosis.
Nasr M; Teiama M; Ismail A; Ebada A; Saber S
Drug Deliv Transl Res; 2020 Dec; 10(6):1841-1852. PubMed ID: 32779112
[TBL] [Abstract][Full Text] [Related]
33. Formulation and characterization of biocompatible and stable I.V. itraconazole nanosuspensions stabilized by a new stabilizer polyethylene glycol-poly(β-Benzyl-l-aspartate) (PEG-PBLA).
Zong L; Li X; Wang H; Cao Y; Yin L; Li M; Wei Z; Chen D; Pu X; Han J
Int J Pharm; 2017 Oct; 531(1):108-117. PubMed ID: 28830781
[TBL] [Abstract][Full Text] [Related]
34. Formulation of mucoadhesive vaginal hydrogels insensitive to dilution with vaginal fluids.
Aka-Any-Grah A; Bouchemal K; Koffi A; Agnely F; Zhang M; Djabourov M; Ponchel G
Eur J Pharm Biopharm; 2010 Oct; 76(2):296-303. PubMed ID: 20656027
[TBL] [Abstract][Full Text] [Related]
35. In vitro susceptibility of filamentous fungi from mycotic keratitis to azole drugs.
Shobana CS; Mythili A; Homa M; Galgóczy L; Priya R; Babu Singh YR; Panneerselvam K; Vágvölgyi C; Kredics L; Narendran V; Manikandan P
J Mycol Med; 2015 Mar; 25(1):44-9. PubMed ID: 25541256
[TBL] [Abstract][Full Text] [Related]
36. Natamycin niosomes as a promising ocular nanosized delivery system with ketorolac tromethamine for dual effects for treatment of candida rabbit keratitis; in vitro/in vivo and histopathological studies.
El-Nabarawi MA; Abd El Rehem RT; Teaima M; Abary M; El-Mofty HM; Khafagy MM; Lotfy NM; Salah M
Drug Dev Ind Pharm; 2019 Jun; 45(6):922-936. PubMed ID: 30744431
[TBL] [Abstract][Full Text] [Related]
37. Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections.
Lakhani P; Patil A; Majumdar S
J Ocul Pharmacol Ther; 2019; 35(1):6-22. PubMed ID: 30481082
[TBL] [Abstract][Full Text] [Related]
38. Design and evaluation of itraconazole loaded solid lipid nanoparticulate system for improving the antifungal therapy.
Mukherjee S; Ray S; Thakur RS
Pak J Pharm Sci; 2009 Apr; 22(2):131-8. PubMed ID: 19339221
[TBL] [Abstract][Full Text] [Related]
39. In situ forming and mucoadhesive ophthalmic voriconazole/HPβCD hydrogels for the treatment of fungal keratitis.
Díaz-Tomé V; García-Otero X; Varela-Fernández R; Martín-Pastor M; Conde-Penedo A; Aguiar P; González-Barcia M; Fernández-Ferreiro A; Otero-Espinar FJ
Int J Pharm; 2021 Mar; 597():120318. PubMed ID: 33540021
[TBL] [Abstract][Full Text] [Related]
40. Fluconazole nanoparticles prepared by antisolvent precipitation technique: Physicochemical,
El Sayeh F Abou El Ela A; Abbas Ibrahim M; Alqahtani Y; Almomen A; Sfouq Aleanizy F
Saudi Pharm J; 2021 Jun; 29(6):576-585. PubMed ID: 34194264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
